See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Social Media
Natural Disasters
Floods
Donald Trump
Immigration
Motorsports
Artificial Intelligence
Education
Crime
Golf
Music
South America
Published • loading... • Updated

Aptar Acquires Mod3 Pharma’s Trial Materials Manufacturing Capabilities – RamaOnHealthcare

Summary by ramaonhealthcare.com
The acquisition builds upon a previous partnership focused on providing Phase I and II cGMP services for OINDPs.Aptar Pharma has announced the acquisition
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

ramaonhealthcare.comramaonhealthcare.com

Aptar acquires Mod3 Pharma’s trial materials manufacturing capabilities – RamaOnHealthcare

The acquisition builds upon a previous partnership focused on providing Phase I and II cGMP services for OINDPs.Aptar Pharma has announced the acquisition

Read Full Article
Clinical Trials ArenaClinical Trials Arena

Aptar acquires Mod3 Pharma's trial materials manufacturing capabilities

Aptar Pharma has announced the acquisition of Mod3 Pharma's clinical trial materials manufacturing capabilities from SWK Holdings.The post Aptar acquires Mod3 Pharma’s trial materials manufacturing capabilities appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Thursday, July 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Pharma icon

Pharma

News
For You
SearchBlindspotLocal